• Roberto Sacco, Suelen Cristina Sartoretto, Rodrigo Figueiredo de Brito Resende, de Albuquerque Calasans-MaiaJoseJ0000-0002-1498-726XOrthodontic Department, Dental School, Fluminense Federal University, Rio de Janeiro 24020-140, Brazil., Alexandre Malta Rossi, Victor Hugo de Souza Lima, de Almeida Barros MourãoCarlos FernandoCF0000-0001-5775-0222Department of Periodontology, Dental Research Administration, Tufts University School of Dental Medicine, Boston, MA 02111, USA., Jose Mauro Granjeiro, Julian Yates, and Monica Diuana Calasans-Maia.
• Oral Surgery Department, School of Medical Sciences, Division of Dentistry, The University of Manchester, Coupland 3 Building, Oxford Rd, Manchester M13 9PL, UK.
• Medicina (Kaunas). 2022 Dec 27; 59 (1).

AbstractMedication-related osteonecrosis of the jaw (MRONJ) is considered as a severe adverse side effect of specific drugs such as anti-resorptive and anti-angiogenic medications. Evidence suggests that MRONJ is linked to invasive dental procedures, mainly dentoalveolar surgery. Several preventive strategies to minimize the risk of developing MRONJ have been investigated. However, no investigation has been attempted to evaluate the therapeutic effect of local drug-delivery technology as a preventive strategy protocol. The aim of this study is to evaluate the efficacy of hydroxyapatite-containing doxycycline (HADOX) in rats with high-risk MRONJ development. All the rats used in this study were divided into seven groups. Six groups of rats out of seven were exposed to two different doses of antiresorptive drug therapy for four weeks before undergoing an upper incisor extraction. After 28 days, all the animals were euthanized, and the bone blocks were processed for histological and histomorphometrical evaluation. The histomorphometric analysis confirmed that newly formed bone (NFB) was present in all groups, with significant differences. NFB in the HADOX group treated with zoledronic acid at 4% showed (28.38; C.I. 22.29-34.48), which represents a significant increase compared to HA (15.69; C.I. 4.89-26.48) (p = 0.02). A similar pattern was observed in the HADOX group treated with zoledronic acid 8% ZA treatment (p = 0.001). Conclusions: HADOX did not inhibit any bone repair and reduced early inflammatory response. Hence, HADOX could promote bone healing in patients undergoing antiresorptive drug therapy.

18 keywords...

hide…